Physician profile
Jasjit Singh
NPI 1629002050
$1,018.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $99.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $259.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $123.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $109.25 | 2019-2020 | |
| Genentech USA, INC. | $102.00 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $70.86 | 2019 | |
| Emd Serono, INC. | $46.86 | 2019 | |
| Zyla Life Sciences, INC. | $38.95 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $32.22 | 2019 | |
| Allergan, INC. | $27.14 | 2019 | |
| Horizon Therapeutics Plc | $24.39 | 2019 | |
| Upsher-Smith Laboratories LLC | $17.00 | 2020 | |
| Lundbeck LLC | $14.31 | 2019 | |
| Assertio Therapeutics, INC. | $13.60 | 2019 | |
| Harmony Biosciences LLC | $13.37 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.